BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court

Legal Action and Patent Infringement - BioMarin Pharmaceutical Inc has initiated a legal action against Ascendis Pharma A/S for infringement of European patent EP 3 175 863 B1 at the Unified Patent Court (UPC) in Munich, Germany [1] - The patent covers long-acting variants of C-Type Natriuretic Peptide (CNP) [1] - The legal action is based on BioMarin's belief that Ascendis' TransCon CNP investigational product and its development program in Germany and elsewhere in Europe infringe BioMarin's patent [2] - The BioMarin patent was confirmed by the European Patent Office's Opposition Division in 2024 [2] Unified Patent Court (UPC) Jurisdiction - The UPC, which formally started in June 2023, has jurisdiction over European patents for 18 European member states that have ratified the Unitary Patents (UPs) [3] - These member states include Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Portugal, Romania, Slovenia, and Sweden [3] Company Background and Commitment - BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient [4] - The company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline [4] - BioMarin is committed to protecting the important inventions its scientists make for patients around the world, including the more than 15 years of scientific research that supported VOXZOGO® and BMN 333, its long-acting CNP [4] Trademarks and Contacts - BioMarin® and VOXZOGO® are registered trademarks of BioMarin Pharmaceutical Inc [6] - Contacts for investors and media are Traci McCarty and Andrew Villani, respectively [7]